Brought to you by 
Digital Gene and Recordati form atherosclerosis pact
03 Aug 1999
Executive Summary
Digital Gene Technologies (Total Gene Expression Analysis technology) will work with Recordati (publicly traded Italian ethical and OTC company, and a founding DGT shareholder) in an R&D alliance focused on atherosclerosis.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Digital Gene and Recordati form atherosclerosis pact
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice